tiprankstipranks
Blurbs

Maxim Group Keeps Their Buy Rating on Gilead Sciences (GILD)

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Gilead Sciences (GILDResearch Report), with a price target of $92.00. The company’s shares closed yesterday at $86.36.

Okunewitch covers the Healthcare sector, focusing on stocks such as Mediwound, Kiora Pharmaceuticals, and Citius Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -19.8% and a 32.35% success rate on recommended stocks.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $91.53, implying a 5.99% upside from current levels. In a report released on February 3, Piper Sandler also maintained a Buy rating on the stock with a $112.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.39 billion and a net profit of $1.64 billion. In comparison, last year the company earned a revenue of $7.24 billion and had a net profit of $382 million

Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in November 2022, Diane Wilfong, the SVP, Controller & CAO of GILD sold 6,416.00 shares for a total of $535,736.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.

Read More on GILD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles